Results 261 to 270 of about 15,139,370 (299)
Some of the next articles are maybe not open access.
Long-term immune related adverse events
Current Opinion in OncologyPurpose of review Long-term immune related adverse events (irAEs) are an increasing reality in cancer patients treated with immune checkpoint inhibitors (ICIs) but remain under-reported. With the number of ICI treated patients increasing, we here aimed to expose the current evidence on their clinical ...
Leo, Plaçais, Olivier, Lambotte
openaire +2 more sources
Cutaneous immune-related adverse events to checkpoint inhibitors
Clinics in Dermatology, 2020The development of immunotherapy has led to a paradigm shift in the treatment of both solid and hematologic malignancies. As immunomodulatory therapies are employed with increasing frequency, a greater number of immune-related adverse reactions are being reported, and the majority of these involve the skin.
Neeta, Malviya +3 more
openaire +2 more sources
T cell dynamism and immune-related adverse events
Cancer Cell, 2023Immune-related adverse events (irAEs) are a major complication of immune checkpoint inhibitors (ICIs) and occur in an unpredictable fashion. In a Med article, Nunez et al. profile peripheral blood markers in patients treated with ICIs, identifying that dynamic changes in proliferating T cells and cytokine upregulation are associated with irAEs.
Douglas B, Johnson, Justin M, Balko
openaire +2 more sources
Immune-Related Oral, Otologic, and Ocular Adverse Events
2021Emerging immunotherapeutic agents, including immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1), have revolutionized cancer treatment.
Nagham, Al-Zubidi +7 more
openaire +2 more sources
Pitfalls and Immune-Related Adverse Events
2019The role of imaging including FDG PET/CT in response assessment, identification, and monitoring of immune-related adverse events (irAEs) is becoming more important given recent accelerated approvals of immunotherapeutic agents for several tumor types that previously had an extremely poor prognosis and lack of therapeutic options.
Amir Iravani, Rodney J. Hicks
openaire +1 more source
Imaging in Rheumatic Immune-related Adverse Events
Rheumatic Disease Clinics of North AmericaSince their introduction, immune checkpoint inhibitors have revolutionized cancer treatment by harnessing the body's own immune system as a defense against tumor growth. The downside of activating the immune system is the development of immune-related adverse events (irAEs), which mimic autoimmune disease of various organ systems.
Jeremy, Zhang +6 more
openaire +2 more sources
Immune-Related Adverse Event of Immunotherapy: Diabetes
Clinical LaboratoryThe development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells.
Qingqing, Su +8 more
openaire +2 more sources
Checkpoint inhibitors and gastrointestinal immune-related adverse events
Current Opinion in Oncology, 2016Purpose of review Recent development of checkpoint inhibitors is a challenge for oncologists. Indeed, it leads to specific immune adverse events, close to autoimmune disorders, which require a specific management. Colitis is one of the most frequent immune adverse events, in particular with anticytotoxic T-lymphocyte-associated
Simon, Pernot +2 more
openaire +2 more sources
Immune-related gastritis: An orphan immune-related adverse event.
Journal of Clinical Oncologye24138 Background: Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology with a significant impact on patients' survival. However, they are not without shortcomings, with 70-90% of patients experiencing immune-related adverse events (irAEs(.
Tal Etan +3 more
openaire +1 more source
Immune-related adverse events associated with cancer immunotherapy
MedImmunotherapy has become central to cancer care, whether in combination with traditional chemotherapy, as adjuvant therapy, or as primary therapy, and has been demonstrated to be central to treatment of newly diagnosed or relapsed disease in multiple randomized control trials.
Smith Kungwankiattichai +3 more
openaire +2 more sources

